Exhibit 99.1

Press Statement: Roche and Trimeris Comment on Results of RESIST Study

Study presented in an oral late breaker session at the 44^th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

WASHINGTON, D.C. (Nov. 1, 2004) – Roche and Trimeris today applauded results from the tipranavir RESIST-1 Phase III study, which are consistent with data from the TORO studies, showing that in treatment-experienced patients, FUZEON^® (enfuvirtide) markedly enhances the activity of regimens that include an active boosted protease inhibitor (PI). Almost half of patients (47 percent) in the RESIST-1 study who took FUZEON with tipranavir/ritonavir, along with other anti-HIV drugs, achieved HIV levels of less than 400 copies/mL at 24 weeks, and almost one-third (31.8 percent) achieved HIV levels of less than 50 copies/mL. Patients enrolled in the RESIST-1 study were extensively pre-treated, including having exposure to several prior PI regimens.

# # #

Please visit www.Fuzeon.com for full prescribing information on Fuzeon. For US news about Fuzeon studies presented at ICAAC, please see Roche/Trimeris press release dated October 31, 2004.